Genetic diversity in Ebola virus: Phylogenetic and in silico structural studies of Ebola viral proteins

Alba Grifoni; Massimo Amicosante; Alessandra LO Presti; Marta Giovanetti; Eleonora Cella; Massimo Ciccozzi; Marta Giovanetti; Carla Montesano; Vittorio Colizzi; Massimo Amicosante; Alessia Lai; Gianguglielmo Zehender; Eleonora Cella; Silvia Angeletti; Massimo Ciccozzi

Return

Genetic diversity in Ebola virus: Phylogenetic and in silico structural studies of Ebola viral proteins

Author: Alba GRIFONI ¹ ; Massimo AMICOSANTE ¹ ; Alessandra LO PRESTI ² ; Marta GIOVANETTI ² ; Eleonora CELLA ² ; Massimo CICCOZZI ² ; Marta GIOVANETTI ³ ; Carla MONTESANO ³ ; Vittorio COLIZZI ³ ; Massimo AMICOSANTE ⁴ ; Alessia LAI ⁵ ; Gianguglielmo ZEHENDER ⁵ ; Eleonora CELLA ⁶ ; Silvia ANGELETTI ⁷ ; Massimo CICCOZZI ⁸
Author Information

1. ProxAgen Ltd
2. Department of Infectious Parasitic and Immunomediated Diseases, National Institute of Health
3. Department of Biology, University of Rome 'Tor Vergata'
4. Department of Biomedicine and Prevention, University of Rome 'Tor Vergata'
5. Laboratory of Infectious Diseases and Tropical Medicine, University of Milan
6. Department of Public Health and Infectious Diseases, Sapienza University of Rome
7. Clinical Pathology and Microbiology Laboratory, University Hospital Campus Bio-Medico of Rome
8. University Campus Bio-Medico
Publication Type:Journal Article
Keywords: Ebola virus; Evolutionary analysis; Proteins
From: Asian Pacific Journal of Tropical Medicine 2016;9(4):337-343
CountryChina
Language:Chinese
Abstract: Objective: To explore the genetic diversity and the modification of antibody response in the recent outbreak of Ebola Virus. Methods: Sequences retrieved from public databases, the selective pressure analysis and the homology modeling based on the all protein (nucleoprotein, VP35, VP40, soluble glycoprotein, small soluble glycoprotein, VP30, VP24 and polymerase) were used. Results: Structural proteins VP24, VP30, VP35 and VP40 showed relative conserved sequences making them suitable target candidates for antiviral treatment. On the contrary, nucleoprotein, polymerase and soluble glycoprotein have high mutation frequency. Conclusions: Data from this study point out important aspects of Ebola virus sequence variability that for epitope and vaccine design should be considered for appropriate targeting of conserved protein regions.